Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 8/20 | 0.72 |
| ▸ | NR3C2 | P08235 | 8/20 | 0.72 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.72 |
| ▸ | PGR | P06401 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.72 |
| ▸ | SHBG | P04278 | 2/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.59 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.59 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10597597 | 1.00 | HIF1A (0.72) | HIF1ANR3C2NR3C1HSD17B10PGR | |
| SCHEMBL10062395 | 1.00 | HIF1A (0.72) | HIF1ANR3C2NR3C1HSD17B10PGR | |
| SCHEMBL10597610 | 1.00 | HIF1A (0.72) | HIF1ANR3C2NR3C1HSD17B10PGR | |
| SCHEMBL147438 | 1.00 | HIF1A (0.72) | HIF1ANR3C2NR3C1HSD17B10PGR | |
| SCHEMBL141636 | 0.91 | HIF1A (0.73) | HIF1ANR3C2NR3C1HSD17B10PGR | |
| SCHEMBL8712243 | 0.91 | HIF1A (0.73) | HIF1ANR3C2NR3C1HSD17B10PGR | |
| SCHEMBL27991637 | 0.91 | HIF1A (0.73) | HIF1ANR3C2NR3C1HSD17B10PGR | |
| SCHEMBL141635 | 0.91 | HIF1A (0.73) | HIF1ANR3C2NR3C1HSD17B10PGR | |
| SCHEMBL10497312 | 0.89 | HIF1A (0.70) | HIF1ANR3C2NR3C1HSD17B10PGR | |
| SCHEMBL10062789 | 0.89 | HIF1A (0.64) | HIF1ANR3C2NR3C1HSD17B10PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178726-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-07-12 | — | — | US | disclosed |
| EP-2207788-A1 | STEROIDAL [3, 2-C]PYRAZOLE COMPOUNDS, WITH GLUCOCORTICOID ACTIVITY | AstraZeneca AB (SE) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009044200-A1 | STEROIDAL [3, 2-C] PYRAZOLE COMPOUNDS, WITH GLUCOCORTICOID ACTIVITY | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | WO | disclosed |
| EP-0042451-B1 | PROCESS FOR THE PREPARATION OF 11-BETA-HYDROXY STEROIDS | SCHERING AKTIENGESELLSCHAFT (DE) | 1983-06-22 | — | — | EP | disclosed |
| US-4353985-A | FERMENTATION WITH CURVULARIA | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-10-12 | — | — | US | disclosed |
| US-4021459-A | Process for the preparation of 21-halogeno-21-desoxy-17α-acyloxy 20-keto-pregnenes | SCHERING CORPORATION (US) | 1977-05-03 | — | — | US | disclosed |
| US-3992422-A | Process for the preparation of 21-halogeno-21-desoxy-17α-acyloxy-20-keto-pregnenes | SCHERING CORPORATION (US) | 1976-11-16 | — | — | US | disclosed |
| US-3980680-A | Process for the preparation of 21-desoxy-17-acyloxy-4-pregnenes and of 21-iodo-21-desoxy-17-acyl oxy-4-pregnene intermediates useful therein | SCHERING CORPORATION (US) | 1976-09-14 | — | — | US | disclosed |
| US-3956349-A | TRIETHYL ORTHOACETATE, ACID CATALYST | SYNTEX (U.S.A.) INC. (US) | 1976-05-11 | — | — | US | disclosed |
| US-3947409-A | 16-Alkyl-1,4,9(11)-pregnatrienes and 9,11-epoxides thereof | MERCK & CO., INC. (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178726-A1 | NOVEL COMPOUNDS | F12, C1R, CXCR4 | HIF1A 2414/4885NR3C2 546/4885NR3C1 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.